Pneumococcus can cause serious disease, particularly in certain clinical risk groups. Preventing disease through vaccination lowers morbidity and mortality from pneumococcal disease.
New research data have contributed to recent changes in the recommendation and funding arrangements for pneumococcal vaccination in Australia.
Upon completion of this GP education program, you will have the knowledge and tools to identify clinical risk groups for pneumococcal disease, recognise the pneumococcal vaccine types currently recommended and funded in Australia for these at-risk groups and learn strategies for counselling patients to receive pneumococcal vaccination.
This educational activity was developed by MDBriefCase at the request, and with funding from Pfizer.